COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity

Mi-Hyun Lee; Bum-Joon Kim

doi:10.1007/s12275-022-1621-2

Articles

Page Path: HOME > J. Microbiol > Volume 60(3); 2022 > Article

Review
COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity: Mi-Hyun Lee ^1,2, Bum-Joon Kim ^1,2,3; Journal of Microbiology 2022;60(3):321-334.
DOI: https://doi.org/10.1007/s12275-022-1621-2
Published online: February 14, 2022

¹Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea, ²Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea, ³Liver Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea¹Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea, ²Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea, ³Liver Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea

Corresponding author: Bum-Joon Kim , Tel: +82-2-740-8315,

Received: 30 November 2021 • Revised: 30 December 2021 • Accepted: 31 December 2021

prev next

62 Views
0 Download
11 Web of Science
13 Crossref
13 Scopus

Full Article

Abstract

Severe acute respiratory syndrome coronavirus 2 virus (SARSCoV- 2) infection, which causes coronavirus disease 2019 (COVID-19), has led to many cases and deaths worldwide. Therefore, a number of vaccine candidates have been developed to control the COVID-19 pandemic. Of these, to date, 21 vaccines have received emergency approval for human use in at least one country. However, the recent global emergence of SARS-CoV-2 variants has compromised the efficacy of the currently available vaccines. To protect against these variants, the use of vaccines that modulate T cell-mediated immune responses or innate immune cell memory function, termed trained immunity, is needed. The major advantage of a vaccine that uses bacteria or viral systems for the delivery of COVID-19 antigens is the ability to induce both T cell-mediated and humoral immune responses. In addition, such vaccine systems can also exert off-target effects via the vector itself, mediated partly through trained immunity; compared to other vaccine platforms, suggesting that this approach can provide better protection against even vaccine escape variants. This review presents the current status of the development of COVID-19 vaccines based on recombinant viral and bacterial delivery systems. We also discuss the current status of the use of licensed live vaccines for other infections, including BCG, oral polio and MMR vaccines, to prevent COVID-19 infections.

Keywords: alcohol;cigarette;co-occurrence;intestinal microbiota;microbiota-host interaction

Figure & Data

References

Citations

Citations to this article as recorded by

Real-time infectious disease endurance indicator system for scientific decisions using machine learning and rapid data processing
Shivendra Dubey, Dinesh Kumar Verma, Mahesh Kumar
PeerJ Computer Science.2024; 10: e2062. CrossRef
What is the role of microbial biotechnology and genetic engineering in medicine?
Fernando Santos‐Beneit
MicrobiologyOpen.2024;[Epub] CrossRef
Previous BCG vaccination is associated with less severe clinical progression of COVID-19
Susan Martins Pereira, Florisneide Rodrigues Barreto, Ramon Andrade de Souza, Carlos Antonio de Souza Teles Santos, Marcos Pereira, Enny Santos da Paixão, Carla Cristina Oliveira de Jesus Lima, Marcio Santos da Natividade, Ana Angélica Bulcão Portela Lind
BMC Medicine.2023;[Epub] CrossRef
COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type
Areg A. Totolian, Viacheslav S. Smirnov, Alexei A. Krasnov, Edward S. Ramsay, Vladimir G. Dedkov, Anna Y. Popova
Viruses.2023; 15(11): 2181. CrossRef
The Cellular and Epigenetic Aspects of Trained Immunity and Prospects for Creation of Universal Vaccines on the Eve of More Frequent Pandemics
I. V. Alekseenko, R. G. Vasilov, L. G. Kondratyeva, S. V. Kostrov, I. P. Chernov, E. D. Sverdlov
Russian Journal of Genetics.2023; 59(9): 851. CrossRef
Coronavirus XBB.1.5 as an Indicator of the Long-Term Continuation of the Covid-19 pandemic. What Next for Vaccination?
E. P. Kharchenko
Epidemiology and Vaccinal Prevention.2023; 22(2): 12. CrossRef
Extracellular Vesicle-Based SARS-CoV-2 Vaccine
Yasunari Matsuzaka, Ryu Yashiro
Vaccines.2023; 11(3): 539. CrossRef
Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung
Journal of Microbiology and Biotechnology.2023; 33(12): 1587. CrossRef
Leishmania tarentolae: a vaccine platform to target dendritic cells and a surrogate pathogen for next generation vaccine research in leishmaniases and viral infections
Claudio Bandi, Jairo Alfonso Mendoza-Roldan, Domenico Otranto, Alessandro Alvaro, Viviane Noll Louzada-Flores, Massimo Pajoro, Ilaria Varotto-Boccazzi, Matteo Brilli, Alessandro Manenti, Emanuele Montomoli, Gianvincenzo Zuccotti, Sara Epis
Parasites & Vectors.2023;[Epub] CrossRef
Cellular and Epigenetic Aspects of Trained Immunity and Prospects for Creation of Universal Vaccines in the Face of Increasingly Frequent Pandemics
I. V. Alekseenko, R. G. Vasilov, L. G. Kondratyeva, S. V. Kostrov, I. P. Chernov, E. D. Sverdlov
Генетика.2023; 59(9): 981. CrossRef
BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists
Andrés Noé, Thanh D. Dang, Christine Axelrad, Emma Burrell, Susie Germano, Sonja Elia, David Burgner, Kirsten P. Perrett, Nigel Curtis, Nicole L. Messina
Frontiers in Immunology.2023;[Epub] CrossRef
The Natural Effect of BCG Vaccination on COVID-19: The Debate Continues
Wenping Gong, Huiru An, Jie Wang, Peng Cheng, Yong Qi
Frontiers in Immunology.2022;[Epub] CrossRef
Two years of COVID-19 pandemic: where are we now?
Jinjong Myoung
Journal of Microbiology.2022; 60(3): 235. CrossRef

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity

J. Microbiol. 2022;60(3):321-334. Published online February 14, 2022

DOI: https://doi.org/10.1007/s12275-022-1621-2

Related articles